ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,794.97
0.10%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. PDS Biotechnology Corporation (PDSB)

  7. PDS Biotechnology Corporation (PDSB) Noticias

PDSB

PDS Biotechnology (PDSB)

PDS Biotechnology Corporation
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:PDSB
FechaHoraFuenteTítuloSímboloCompañía
15/05/202416:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PDSBPDS Biotechnology Corporation
15/05/202407:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
23/01/202415:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PDSBPDS Biotechnology Corporation
23/01/202415:31Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PDSBPDS Biotechnology Corporation
22/01/202415:45GlobeNewswire Inc.PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical OfficerNASDAQ:PDSBPDS Biotechnology Corporation
16/01/202407:00GlobeNewswire Inc.PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:PDSBPDS Biotechnology Corporation
04/12/202315:50GlobeNewswire Inc.PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PDSBPDS Biotechnology Corporation
28/11/202306:30GlobeNewswire Inc.PDS Biotech Appoints Lars Boesgaard as Chief Financial OfficerNASDAQ:PDSBPDS Biotechnology Corporation
14/11/202306:30GlobeNewswire Inc.PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:PDSBPDS Biotechnology Corporation
09/11/202307:00GlobeNewswire Inc.PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 MonthsNASDAQ:PDSBPDS Biotechnology Corporation
07/11/202307:00GlobeNewswire Inc.PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial ResultsNASDAQ:PDSBPDS Biotechnology Corporation
23/10/202307:00GlobeNewswire Inc.PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMONASDAQ:PDSBPDS Biotechnology Corporation
11/10/202307:00GlobeNewswire Inc.PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate CancerNASDAQ:PDSBPDS Biotechnology Corporation
03/10/202306:00GlobeNewswire Inc.PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)NASDAQ:PDSBPDS Biotechnology Corporation
02/10/202307:00GlobeNewswire Inc.PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)NASDAQ:PDSBPDS Biotechnology Corporation
26/09/202307:00GlobeNewswire Inc.PDS Biotech to Present at the LD Micro Main Event XVINASDAQ:PDSBPDS Biotechnology Corporation
25/09/202307:00GlobeNewswire Inc.PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101NASDAQ:PDSBPDS Biotechnology Corporation
20/09/202315:05GlobeNewswire Inc.PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:PDSBPDS Biotechnology Corporation
20/09/202307:00GlobeNewswire Inc.PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical StudiesNASDAQ:PDSBPDS Biotechnology Corporation
13/09/202307:00GlobeNewswire Inc.PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023NASDAQ:PDSBPDS Biotechnology Corporation
06/09/202315:05GlobeNewswire Inc.PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:PDSBPDS Biotechnology Corporation
06/09/202307:00GlobeNewswire Inc.PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI ConferenceNASDAQ:PDSBPDS Biotechnology Corporation
16/08/202307:00GlobeNewswire Inc.PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual MeetingNASDAQ:PDSBPDS Biotechnology Corporation
14/08/202306:30GlobeNewswire Inc.PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:PDSBPDS Biotechnology Corporation
14/08/202306:00GlobeNewswire Inc.PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 TrialNASDAQ:PDSBPDS Biotechnology Corporation
07/08/202307:00GlobeNewswire Inc.PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial ResultsNASDAQ:PDSBPDS Biotechnology Corporation
02/08/202307:00GlobeNewswire Inc.PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023NASDAQ:PDSBPDS Biotechnology Corporation
25/07/202307:00GlobeNewswire Inc.PDS Biotech to Present Immune Response Data from Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023NASDAQ:PDSBPDS Biotechnology Corporation
17/07/202307:00GlobeNewswire Inc.PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023NASDAQ:PDSBPDS Biotechnology Corporation
11/07/202307:00GlobeNewswire Inc.PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301NASDAQ:PDSBPDS Biotechnology Corporation
 Showing the most relevant articles for your search:NASDAQ:PDSB

Su Consulta Reciente

USOTC
BNPQY
BNP Paribas (QX)
USOTC
BASFY
BASF (QX)
NASDAQ
TSLA
Tesla
FX
EURUSD
Euro vs US Dollar
NASDAQ
GOOGL
Alphabet
COIN
ETHUSD
Ethereum
NYSE
DIS
Walt Disney
SPI
SP500
S&P 500
AMEX
XLF
Financial Select Sector
CCOM
US30
US 30
NASDAQ
NVDA
NVIDIA
CCOM
US500
US 500
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
MSFT
Microsoft
AMEX
XLV
Health Care Select Sector
NYSE
MCD
McDonalds
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados